NCT03455140 : A Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Treatment<br/>TrialTypeTreatment
Trial

One/TwoPhase One/Two

1-25Age 1-25

Advanced CancersCancer LocationMulti-Cancer
Trial

Treatment | Blood / Myeloma / Lymphoma,Brain and spinal cord,SarcomaGlioma,Leukaemia,Neuroblastoma,Sarcoma

Trial Overview Read MoreRead more

This phase I/II trial evaluates the safety and activity of an anti-cancer drug in children with relapsed/refractory leukaemia, neuroblastoma, sarcoma and high grade glioma..
 

This trial is treating patients with Relapsed/refractory leukaemia, Neuroblastoma, Sarcoma and High grade gliomas (brain cancers).

This is a Systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had a certain type of treatment or surgical procedure.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has not spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults

Other Non-Commercial Sponsor

University of Birmingham

Summary

Eligible patients will be assigned to experimental groups dependant on their condition; Leukaemia, Neuroblastoma, Sarcomas and High Grade Glioma. Each group will receive a weekly IV infusion of PEG- BCT-100.

Recruiting Hospitals Read MoreRead more

Royal Childrens Hospital
Parkville
Trial Coordinator
CCC.ClinicalTrials@rch.org.au

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next